A law firm is investigating GRAIL, Inc. officers and directors for potential wrongdoing on behalf of long-term investors. This probe follows a lawsuit alleging the company violated securities laws by making misleading statements.
The lawsuit claims GRAIL misrepresented the probability of its NHS-Galleri trial achieving its primary endpoint. On February 19, 2026, GRAIL announced the trial failed to demonstrate a statistically significant reduction in Stage III-IV cancers.
GRAIL’s stock price declined sharply following the announcement. The investigation will determine if certain executives are liable for the alleged false statements made to investors.